Parkinson’s is the fastest growing neurological condition in the world and affects around 153,000 people in the UK.

UK-based startup Vicebio has raised $100m to advance its “next-generation vaccines” for respiratory illnesses, including ...

Shares of GSK PLC GSK inched down 0.55% to £15.28 Monday, on what proved to be an all-around favorable trading session for ...

New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of NeuroblastomaStudy ...

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

There hasn’t been a new class of drugs approved to help smokers quit since Pfizer's Chantix reached the market nearly two ...

The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...

Tickets sold out so quickly for today’s Labour party conference “business day” that it was dubbed the corporate equivalent of ...